# GLP-1 Off Label Use: What It Means, Uses, Risks (2026)

Source: https://www.dietglp.com/blog/glp-1-off-label-use/
Published: 2026-11-03
Keywords: glp-1 off label, glp 1 off label, glp-1 off label use, off label uses of glp 1, glp-1 off label uses, off label use for glp 1, glp 1 off label benefits, what does off label glp 1 mean, how to get glp 1 off label, cost of glp 1 off label, glp 1 off label reddit, glp-1 off label for inflammation, glp 1 agonist off label use, off label glp 1 prescribing trends

**TL;DR:** GLP-1 off label use means a doctor prescribes a GLP-1 medicine for a reason, or a person, that is not on its FDA label, such as Ozempic for weight loss without diabetes or any GLP-1 for someone with a normal BMI. It is legal, and it is common: a study in the journal Obesity found more than 1.1 million US adults got a GLP-1 from 2021 to 2025 without an approved reason in their records, about a third of them with a normal BMI. The risks and benefits for those uses are not well studied, insurance often will not pay, and the decision belongs with your prescriber. If you are on one, [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) helps you protect muscle with one protein target and one 20-minute workout a day.

What does "GLP-1 off label" mean, and should you worry about it? Here is the plain answer. A GLP-1 is used off label when a doctor prescribes it for something its FDA label does not cover. Ozempic for weight loss in someone without diabetes is the classic example. So is any GLP-1 for a person whose BMI is below the label's cutoff. It is legal. It is also growing fast: researchers found **more than 1.1 million US adults** got a GLP-1 without an approved reason in their medical records between 2021 and 2025.

Off label does not mean fake or illegal. It means the FDA has not reviewed that specific use. This guide explains what is on each label, the most common off label uses, what the research says about each one, and the questions to ask before you start.

## What does off label GLP-1 mean?

Every FDA-approved drug has a label, also called prescribing information. It lists who the drug is for, at what doses, based on the trials the FDA reviewed. When a doctor prescribes it outside those lines, that is off label use.

The FDA's own patient page says doctors may prescribe an approved drug for an unapproved use when they judge it medically appropriate for a patient. What the law blocks is drug companies marketing those uses.

Off label use can mean three different things:
- **A different condition.** For example, a GLP-1 for PCOS or alcohol use.
- **A different person.** For example, someone with a normal BMI, or a child below the approved age.
- **A different brand for the same goal.** For example, Ozempic (a diabetes brand) for weight loss, when Wegovy is the weight brand of the same drug.

## What GLP-1 drugs are approved for

This table shows what each label covers. Anything outside it is off label. For the full list with makers and forms, see our [GLP-1 drugs list](/blog/glp-1-drugs-list/).

| Drug | Generic | Approved for (per FDA label) |
|---|---|---|
| Wegovy shot | semaglutide 2.4 mg | Weight loss (adults with BMI 30+, or 27+ with a weight-related condition; teens 12+), heart risk reduction, MASH liver disease |
| Wegovy pill | oral semaglutide 25 mg | Weight loss, heart risk reduction |
| Zepbound | tirzepatide | Weight loss in adults, obstructive sleep apnea with obesity |
| Foundayo | orforglipron | Weight loss in adults |
| Saxenda | liraglutide 3 mg | Weight loss (adults and teens 12+) |
| Ozempic | semaglutide | Type 2 diabetes, plus heart and kidney risk reduction in type 2 diabetes |
| Mounjaro | tirzepatide | Type 2 diabetes (age 10+) |
| Rybelsus | oral semaglutide | Type 2 diabetes |

Notice that Ozempic and Wegovy are the same drug, and Mounjaro and Zepbound are the same drug. The labels differ because the companies ran different trials for each brand.

## How many people take GLP-1s off label? The new study

The study behind this week's headlines was led by Dr. Babak Orandi at NYU Langone Health and published in the journal *Obesity* in September 2026. Medscape and other outlets were still covering it on November 3. The team looked at electronic health records from the Epic Cosmos database, January 2021 to December 2025.

| Finding | Number |
|---|---|
| Adults with no type 2 diabetes or qualifying weight diagnosis in their records | 92,415,648 |
| Of those, prescribed a GLP-1 anyway | 1,133,953 (about 1.2%) |
| Share prescribed in 2021 vs 2025 | about 0.11% vs 1.5% |
| Off label users with a normal BMI | about 1 in 3 |
| History of eating disorder vs non-users | about 6 times more common |
| Drugs counted | liraglutide, semaglutide, tirzepatide |

Off label users were more likely to be women, white, privately insured and from better-off areas. The authors wrote that "the risk–benefit profile in these populations remains uncertain."

Keep the limits in mind. A missing diagnosis in a chart does not prove a prescription was wrong. Some people may have lost weight before they joined the database, or had their condition recorded somewhere else. Telehealth and compounded GLP-1s were mostly left out, so the real number could be higher.

## Off label uses of GLP-1 and what the evidence says

These are the off label uses people search for most. Here is where each one stands.

| Off label use | FDA approved? | What the evidence shows |
|---|---|---|
| Ozempic or Mounjaro for weight loss without diabetes | No (the weight brands are) | Same drugs as Wegovy and Zepbound, which have large weight-loss trials |
| Weight loss with a normal BMI | No | Not studied in large trials; safety unclear |
| PCOS | No | Small studies; see our [GLP-1 for PCOS guide](/blog/glp1-and-pcos/) |
| Type 1 diabetes | No | Studied, not approved; see [GLP-1 and type 1 diabetes](/blog/glp-1-type-1-diabetes/) |
| Alcohol use disorder | No | One 48-person, 9-week phase 2 trial cut drinks on drinking days and cravings |
| Alzheimer's disease | No | Two phase 3 trials (EVOKE, 3,808 people) did not slow the disease |
| Inflammation | No | Early research only |

The alcohol trial was published in *JAMA Psychiatry* in February 2025. Semaglutide lowered drinks per drinking day and weekly cravings, but did not change total drinks per day. The authors called for larger and longer studies. We cover this more in [GLP-1 for addiction](/blog/glp-1-for-addiction/).

The Alzheimer's result is a good reminder that a promising idea does not always hold up. Novo Nordisk said in November 2025 that oral semaglutide improved some biomarkers but did not delay the disease.

## GLP-1 off label benefits vs risks

The "benefits" people hear about for off label use mostly come from studies in people who fit the label. Those results may not carry over to someone at a normal weight.

What to weigh:
- **Label side effects still apply.** The most common are nausea, diarrhea, vomiting and constipation. The labels also warn about pancreatitis, gallbladder problems and a boxed warning about thyroid C-cell tumors in rodents.
- **Muscle loss.** In weight-loss trials, part of the weight lost is lean mass. If you start lean, you have less to spare.
- **Eating disorders.** Appetite loss can feed restriction. Our guide on [GLP-1 medications and eating disorders](/blog/glp-1-medications-and-eating-disorders/) covers the warning signs.
- **Pregnancy.** Talk to your doctor before you take any GLP-1 if you are pregnant or planning to be.

If you do take a GLP-1, for any reason, protecting muscle is the part you control. [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) sets one daily protein target based on your body, gives you one 20-minute strength workout, and tracks your Shape Score so you can see whether you are losing fat or muscle.

## Cost of GLP-1 off label

Insurance is the big catch. Many plans only pay for a GLP-1 with a covered diagnosis, such as type 2 diabetes or obesity, and often need prior authorization. An off label prescription may not meet those rules, so you may pay the self-pay price. Our [GLP-1 cost and coverage guide](/blog/glp1-cost-and-coverage/) explains how coverage decisions work.

Compounded or "research" versions are not a safe shortcut. The FDA does not check compounded drugs for safety or quality before they are sold. See our [compounded GLP-1 guide](/blog/compounded-glp1/).

## How to get GLP-1 off label: questions for your doctor

Do not start, change or stop a GLP-1 on your own. If you are thinking about off label use, bring these questions to your prescriber:
- Is this use on the label? If not, what evidence supports it for someone like me?
- What are the risks for my weight, age and health history?
- How will we know it is working, and when would we stop?
- Will my insurance cover it, and what will it cost if not?
- How do I protect muscle while I am on it?

## The bottom line

GLP-1 off label use is legal and very common, and it is growing. For some uses, like a diabetes brand used for weight loss, the science is strong. For others, like weight loss at a normal BMI, nobody knows the long-term balance of risk and benefit. Make the call with your doctor, and if you start, make protein and strength training part of the plan. [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) keeps both simple, one target and one workout a day.

## Sources

- [FDA: Understanding unapproved use of approved drugs "off label"](https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label)
- [Gizmodo: More than 1 million Americans are taking GLP-1s without an approved reason (Sep 24, 2026), on Orandi et al. in Obesity](https://gizmodo.com/more-than-1-million-americans-are-taking-ozempic-and-other-glp-1s-without-an-approved-reason-is-that-actually-a-problem-2000816772)
- [NYU Langone Health in the News, September 23, 2026](https://nyulangone.org/news/nyu-langone-health-news-wednesday-september-23-2026)
- [Hendershot CS et al. Once-weekly semaglutide in adults with alcohol use disorder, JAMA Psychiatry 2025](https://doi.org/10.1001/jamapsychiatry.2024.4789)
- [Novo Nordisk: Topline results from the EVOKE and EVOKE+ trials (November 24, 2025)](https://www.novonordisk.com/news-and-media/news-and-ir-materials/news-details.html?id=916462)
- [Wegovy (semaglutide) prescribing information, rev. June 2026 (DailyMed)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=ee06186f-2aa3-4990-a760-757579d8f77b)
- [Zepbound (tirzepatide) prescribing information (DailyMed)](https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=487cd7e7-434c-4925-99fa-aa80b1cc776b)


## Frequently asked questions

**Q: What does off label GLP-1 mean?**

A: It means a GLP-1 medicine is prescribed for a use, age group or dose that is not on its FDA-approved label. The drug itself is FDA approved, but that specific use has not been reviewed by the FDA. Doctors are allowed to prescribe this way when they judge it is right for a patient.

**Q: Is it legal to prescribe a GLP-1 off label?**

A: Yes. The FDA says that once a drug is approved, health care providers may prescribe it for an unapproved use when they judge it medically appropriate. What drug companies cannot do is market a drug for an unapproved use.

**Q: How many people take GLP-1s off label?**

A: A study by NYU Langone researchers in the journal Obesity, published in September 2026, found 1,133,953 US adults were prescribed a GLP-1 from 2021 to 2025 without type 2 diabetes or a qualifying weight diagnosis in their records. The share rose from about 0.11% to 1.5% of people without an approved reason. Telehealth and compounded prescriptions were mostly not counted, so the true number may be higher.

**Q: What are the off label uses of GLP-1?**

A: The most common are diabetes brands like Ozempic or Mounjaro used for weight loss alone, and weight loss in people whose BMI is below the label cutoffs. GLP-1s are also being studied for PCOS, type 1 diabetes, alcohol use and inflammation, but none of those uses is FDA approved.

**Q: Does insurance cover off label GLP-1?**

A: Often not. Many plans require prior authorization and a covered diagnosis, such as type 2 diabetes or obesity, before they pay. Without that, you may be paying the self-pay price. Ask your plan before you fill.

**Q: Is it safe to take a GLP-1 with a normal BMI?**

A: Nobody knows for sure. The big trials enrolled people with obesity, or overweight plus a weight-related condition, so there is little safety data for people at a normal weight. The study authors said the risk and benefit in these groups remains uncertain. Talk to your doctor, especially if you have a history of an eating disorder.